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A topical pharmaceutical cream containing the active pharmaceutical
ingredients (APIs) betamethasone-17-valerate and fusidic acid has
been developed for the treatment of inflammatory skin conditions
and associated secondary infections. In this work, a novel stability-
indicating RP-HPLC method has been developed for the simultaneous
quantitation of impurities of both APIs present in this cream. The
HPLC column was a 150 mm3 4.6 mm I.D. YMC-Pack Pro C18 col-
umn with 3 mm particles. The column-oven temperature was main-
tained at 408C and UV detection at 235 nm was used. A gradient
programme was employed at a flow rate of 0.7 mL/min. Mobile
phase A comprised of a 16:21:21:42 (v/v/v/v) mixture of methanol,
10 g/L phosphoric acid, HPLC grade water and acetonitrile. Mobile
phase B comprised of a 24:5:5:66 (v/v/v/v) mixture of methanol,
10 g/L phosphoric acid, HPLC gradewater and acetonitrile. The meth-
od has been validated according to current International Conference
on Harmonisation (ICH) guidelines and applied during formulation de-
velopment and stability studies. The procedure has been shown to be
stability-indicating for the topical cream.
Introduction
Dermatological disorders, such as eczema and psoriasis, can have a
debilitating effect on the quality of life of affected patients due to
their very obvious symptoms, including severe inflammation, itch-
ing, bleeding and excess skin growth. Further complications often
arise due to secondary infections of open wounds caused by pick-
ing or scratching of the affected areas by the patient. A common
treatment for these disorders is the use of topical glucocorticoids,
such as hydrocortisone and betamethasone, together with antibi-
otic agents including fusidic acid (FA) and gentamicin sulfate. For
this purpose a topical pharmaceutical preparation containing the
active pharmaceutical ingredients (APIs) betamethasone-17-
valerate (BV) and fusidic acid (Figure 1) has been developed.
Current international guidelines (1, 2) require that degrada-
tion products of APIs in finished pharmaceutical products are
quantified at release and also during the shelf-life of the product.
This is to guarantee an acceptable level of quality by ensuring
that (1) the APIs do not degrade to such an extent that the effi-
cacy of the product is diminished and (2) the levels of potentially
toxic impurities, arising through degradation of these APIs, are
maintained below well-defined limits. To minimize degradation,
the APIs should be formulated in a suitably stable vehicle. This
is the goal of formulation development and this process requires
the employment of a stability-indicating analytical procedure.
None of the analytical methods reported in the literature are
suitable for the simultaneous analysis of impurities of both BV
and FA in a single chromatographic run. There are methods
available for the analysis of the single APIs in topical formulations,
e.g. Po et al. (3) developed an HPLC procedure for the analysis of
BV and its degradation products in topical preparations. The
available methods, however, are not suitable for the present anal-
ysis since they are not selective for all relevant impurities. With
regard to FA, the vast majority of published methods are only suit-
able for the analysis of the main component, i.e. the API, and do
not consider potential impurities. Furthermore, many of the pub-
lished procedures are often poorly selective, being based on
methods such as UV-Vis spectrophotometry (4) or atomic ab-
sorption spectrometry (5) which are not stability-indicating.
Shaikh et al. (6) published a method for the simultaneous quan-
titation of chlorocresol, mometasone furoate and FA in creams.
This method is capable of separating and quantifying the impurity
3-didehydrofusidic acid (3-ketofusidic acid), which is one of the
main impurities of FA. However, 14 other impurities related to
FA have been described, many of which are potential degradation
products (7). These impurities have not been considered in any of
the peer-reviewed literature methods found.
Consequently, it was necessary to develop a new procedure
for the selective analysis of impurities of both active substances.
The analysis of both APIs with the aid of a single HPLC run would
significantly simplify laboratory analysis, thus saving time and re-
ducing costs.
In this paper the development of a novel stability-indicating
RP-HPLC method for the simultaneous quantitation of impurities
of both BV and FA in a single chromatographic run is reported.
The method has been validated according to current International
Conference on Harmonisation (ICH) guidelines and applied to de-
velopment formulations and stability samples of cream.
Materials and methods
Reagents
Fusidic acid hemihydrate and betamethasone-17-valerate were pur-
chased from OJSC Biosintez (Penza, Russia) and Crystal Pharma
(Valladolid, Spain), respectively. Both APIs were of Ph. Eur. Grade.
Gradient grade methanol and acetonitrile were purchased
from VWR International GmbH (Darmstadt, Germany). Purified
water was obtained from the in-house purification system at
mibe GmbH Arzneimittel (Brehna, Germany). Phosphoric acid
(85%, analysis grade, d ¼ 1.71 g/mL) was purchased from
Merck (Darmstadt, Germany). All cream samples were provided
by mibe GmbH Arzneimittel (Brehna, Germany). 3-Ketofusidic
acid, betamethasone-21-valerate, “fusidic acid for peak identifica-
tion CRS” and “fusidic acid impurity mixture CRS” were pur-
chased from the European Directorate for the Quality of
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Medicines and Healthcare (EDQM). Betamethasone was pur-
chased from Sigma-Aldrich.
Instrumentation
Shimadzu Prominence HPLC Systems (Shimadzu, Japan) were
used for method development and validation. The HPLC systems
were equipped with a binary pump (LC-20AD), a temperature-
controlled auto-sampler (SIL-20ACHT), a temperature-controlled
column compartment (CTO-20AC) as well as an on-line degasser
(DGU-20A5). A (SPD-M20A) DAD detector was employed. The
software packages used were SHIMADZU LCsolution version
1.24 SP1 and SHIMADZU Class-VP version 6.14 SP2A.
Chromatographic conditions and sample preparation
The employed HPLC method is described in Table I. Samples
were prepared by weighing 5.00 g of cream into a 50.0 mL
Figure 1. (a) Chemical structures of the main degradation products of the APIs found in the cream. (b) Degradation pathway of betamethasone-17-valerate.
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volumetric flask, adding 30 mL of acetonitrile and suspending by
shaking in a water bath at 658C. The increased temperature al-
lows for complete suspension of the cream by facilitating the
melting of the fatty components, e.g. Vaseline. Thorough mixing
was ensured with the help of a vortexing machine. The APIs were
extracted into solution by shaking the suspension on a flat-bed
shaker at 200 shakes per minute. The mixture was allowed to
cool to room temperature before being made up to volume with
acetonitrile. Unwanted fatty components were “frozen-out” by
placing the suspension in a freezer (2208C) for 20 min. A por-
tion of the cold suspension was then centrifuged at 3000 rpm
for 5 min. The resulting supernatant was removed and allowed
to warm to room temperature before dilution. This prevents
any temperature related dilution errors.
A portion of the supernatantwas diluted 1 : 2 (v/v)with purified
water. This served to further aid the precipitation of unwantedma-
trix components and also to improve peak symmetry by reducing
sample solvent strength. Finally, the solutionwas filtered through a
0.45 mm regenerated cellulose filter (Macherey-Nagel, Germany)
into a suitable HPLC vial. The concentrations of the APIs were
1000.0 and 60.70 mg/mL for FA and BV, respectively. The impuri-
ties were quantified against a 0.5% external standard prepared by
dissolving 40.0 mg of FA and 2.428 mg of BV in 30 mL of acetoni-
trile in a 50.0 mL volumetric flask before making up to 50.0 mL
with the same solvent. This solution was then diluted appropriate-
ly with a 50 : 50 (v/v) mixture of acetonitrile and water, giving
concentrations of 5.000 and 0.3035 mg/mL for FA and BV, respec-
tively. The impurities of FA were quantified against the 0.5% FA
standard and the impurities of BV against the 0.5% BV standard.
Results and conclusions
Method development: column, gradient, injection volume
and oven temperature
Fusidic acid hemihydrate has a single carboxylic acid functional
group with a pKa of 5.3 (8). Consequently, the retention time of
FA will be influenced by the pH of the mobile phase. A suitable
mobile phase should have a pH of 2 units below the pKa of the
acidic group, in order to ensure that the molecule remains
completely protonated in solution. For this reason a mobile
phase acidified with phosphoric acid was chosen. BA, on the
other hand, is a neutral compound and its retention on the ana-
lytical column will not be affected by pH.
As starting conditions mobile phase A comprised of a 20 : 40 :
40 (v/v/v) mixture of methanol, acetonitrile and a 10 g/L solu-
tion of phosphoric acid (85%). Mobile Phase B comprised of a
10 : 20 : 70 (v/v/v) mixture of the same solvents. The gradient
programme started with 100% mobile phase A held for 3 min fol-
lowed by an increase to 100% mobile phase B over the next
25 min. 100% B was then held for a further 10 min. The initial
flow rate was 1.0 mL/min.
Through column screening experiments it was found that an
YMC-Pack Pro C18, 150 mm  4.6 mm column with 3.5 mm par-
ticles provided the best overall separation between all impurities.
However, several impurities were still not satisfactorily separated.
In order to achieve an acceptable separation the gradient pro-
gramme, flow-rate and mobile phase composition were altered.
Modification of the initial part of the gradient programme from
100% B for 3 min to 95% A: 5% B for 20 min and reducing the
flow rate to 0.7 mL/min was found to increase resolution be-
tween all of the peaks eluting in this portion of the chromato-
gram. It was also found that reducing the quantity of methanol
in mobile phase B from 200 to 165 mL/L enabled a better sepa-
ration between the impurities betamethasone-21-valerate and
26-oxofusidic acid as well as between the impurities (24R)-
24,25-dihydroxyfusidic acid-21,24-lactone and 26-hydroxyfusi-
dic acid. An injection volume of 50 mL was chosen because of
the requirement to achieve a high level of sensitivity for the im-
purities of BV due to its low concentration in the drug product
(0.64 mg/g) when compared with fusidic acid (20.0 mg/g). Fifty
microliters were also the maximum possible injection volume of
the system.
The available impurities of BV were identified by dissolving an
appropriate quantity of each compound in the sample solvent
and injecting them into the HPLC. Their respective retention
times and relative retention times were recorded and compared
with the peaks in the sample solution. For the known impurities
of fusidic acid, which were not available as pure substances, the
EP standards fusidic acid for peak identification CRS and fusi-
dic acid impurity mixture CRS were used together with infor-
mation about the relative retention times of each impurity as
provided in the draft PHARMEUROPA monograph for fusidic
acid monohydrate API (9). See Figure 2 for an example chromato-
gram of a cream sample.
Method validation
Selectivity
In order to demonstrate the selectivity of the analytical method,
samples of cream which had been stored under accelerated
stability conditions (408C/75% relative humidity) for 12 months
as well as samples stressed under oxidative- (exposure to air, 3
days) and pH stress (pH 7, 408C, 6 months) were measured.
Experience gathered during analytical and formulation devel-
oped had shown that these samples contained all of the relevant
degradation products of the APIs at concentration levels signifi-
cantly higher than would be expected over the normal shelf-life
of the pharmaceutical product (24 months at 258C/60% rela-
tive humidity). These samples were therefore considered to be
Table I
Description of HPLC Method
Column description – YMC-Pack Pro C18, 150  4.6 mm, 3 mm particles
Guard column – Gemini C18, 4.0 mm L  3.0 mm ID (Phenomenex)
Flow rate mL/min 0.7
Mobile Phase A 16 : 21 : 21 : 42 (v/v/v/v)
Methanol/10 g L21 phosphoric acid/HPLC grade
water/acetonitrile
B 24 : 5 : 5 : 66 (v/v/v/v)
Methanol/10 g L21 phosphoric acid/HPLC grade
water/acetonitrile
Wavelength nm 235
Column temperature 8C 40
Auto-sampler temperature 8C 25
Gradient – Time (min) Event % A % B
START Pump A B. 95 5
20.00 Pump A B. 95 5
45.00 Pump A B. 0 100
50.00 Pump A B. 95 5
60.00 Pump A B. STOP –
Injection volume ml 50
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worst case. Stress tests as well as accelerated stability studies
had shown that the impurities betamethasone and betametha-
sone-21-valerate are the predominant degradation products
of BV which are formed in the cream under normal storage
conditions. The degradation scheme of BV is described in
Figure 1b.
The data also showed that the impurities 16-epideacetylfusidic
acid, 16-epideacetylfusidic acid-21,16-lactone, 3-didehydrofusi-
dic acid and 26-hydroxyfusidic acid are the main degradants of
FA observed. 16-Epideacetylfusidic acid is the most abundant
degradant of fusidic acid seen in stress studies. It is generated
by hydrolysis of the acetyl group at position C16. Further reac-
tion of the resulting free hydroxyl group with the neighboring
carboxyl group at C21 forms the cyclic-lactone 16-epideacetylfu-
sidic acid-21,16-lactone, the second most abundant degradant of
FA observed. The structures of the above-mentioned impurities
are provided in Figure 1a. The purity of the main API peaks and
relevant impurities was evaluated using a photodiode array scan
from 200 to 400 nm, whereby spectra were recorded and com-
pared across the entire peak. The peaks were found to be pure
with this method. No interferences from solvent or placebo com-
ponents were observed.
Linearity
The linearity of the detector response for betamethasone,
betamethasone-21-valerate, BV, 3-didehydrofusidic acid and FA
was checked using a 13-point calibration over a suitable range
as detailed in Table II. These substances were chosen because
they were the only impurities which were commercially available
as pure substances. The APIs FA and BV were used as surrogates
for those impurities which were not available. This is common
practice in analytical chemistry. The correlation coefficients of
the best-fitting lines obtained by least-squares regression were
all .0.999. The residual values demonstrated no particular trend.
Precision and accuracy
The repeatability (reproducibility) of the analytical procedure
was checked by preparation and measurement of six sample so-
lutions by Analyst A using HPLC Machine A on Day 1. The sample
had been stressed at 508C for 8 weeks and contained all relevant
degradation products. The relative standard deviation (rsd) of the
content values for each of the impurities was ,5.0%. The inter-
mediate precision was determined by preparation and measure-
ment of a further 6 samples by Analyst B using HPLC Machine B
on Day 2. The rsd values of a total of 12 measurements were also
,5.0%.
The accuracy of the analytical procedure was determined by
preparation and measurement of nine solutions comprising of
placebo which had been spiked with each of the available impu-
rities over the range 0.1–8.0% of the theoretical sample concen-
tration. The recovery rates for each impurity lay between 99.0
and 111.2%. The recovery rates of both APIs were evaluated in
the same fashion and over the same range, with values of 99.0
and 102.9% obtained for BV and FA, respectively.
Solution stability and robustness of HPLC parameters
Solution stability was determined by preparation of standard and
sample solutions and analyses of these solutions at 4 hourly intervals
over a period of 48 h. The solutions were stored at 258C and pro-
tected from light. The active substance BV proved to be stable
Figure 2. Chromatogram of cream sample measured shortly after manufacture. HPLC conditions as provided in Table I. Peak assignment as follows: 1. Betamethasone.
2. 24,25-Dihydro-24,25-dihydroxyfusidic acid. 3. 24,25-Dihydro-24,25-dihydroxyfusidic acid 21,25-lactone. 4. Betamethasone-17-valerate. 5. (24R)-24,25-dihydro-24,25-dihydroxyfusidic
acid-21,24-lactone. 6. 26-Hydroxyfusidic acid. 7. (24S)-24,25-dihydro-24,25-dihydroxyfusidic acid-21,24-lactone. 8. Betamethasone-21-valerate. 9. 26-Oxofusidic acid. 10. 3-
Didehydrofusidic acid. 11. 11-Didehydrofusidic acid. 12. 16-Epideacetylfusidic acid. 13. Fusidic acid. 14. 16-epideacetylfusidic acid-21,16-lactone. 15. Deacetylfusidic acid-21,16-
lactone. 16. 11-Deoxyfusidic acid. U, unknown impurity.
Table II
Data from the Linearity and LOD/LOQ Experiments
Substance Range (%) r Residuals LOD (%) LOQ (%)
Betamethasone 0.1–8.7 0.9999 No trend 0.008 0.029
Betamethasone-21-valerate 0.1–5.8 0.9999 No trend 0.033 0.112
Betamethasone-17-valerate 0.1–8.7 0.9999 No trend 0.029 0.097
3-Didehydrofusidic acid 0.1–6.1 0.9999 No trend 0.003 0.010
Fusidic acid hemihydrate 0.1–7.8 0.9999 No trend 0.002 0.008
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over the measurement period with the content values of relevant
degradation products remaining unchanged. The FA samples
showed a slight increase of 0.05% of the impurity 16-epideacetylfu-
sidic acid over 48 h. This increase was considered negligible. The
content values of all other known impurities remained unchanged.
No new unknown impurities were observed for either of the APIs.
In order to test the robustness of the method, the HPLC param-
eters were deliberately varied from normal conditions as follows:
column temperature (+58C), flow rate (+0.2 mL/min.), volume
of acetonitrile in mobile phase A (+20 mL/L), volume of meth-
anol in mobile phase A (+20 mL/L), volume of the acidic aque-
ous phase in mobile phase A (+20 mL/L), detection wavelength
(+2 nm) and proportion of mobile phase B at begin of gradient
programme (+3%). Some of the conditions tested, e.g. increas-
ing the column-oven temperature by 58C, lead to a co-elution of
the impurities (24S)-24,25-dihydroxyfusidic acid-21,24-lactone
and betamethasone-21-valerate. As a result, a visual examination
of the resolution between critical peak pairs has been adopted as
a system suitability requirement before sample measurement.
Limits of detection (LOD) and quantitation (LOQ)
The limits of detection and quantitation were defined as 3 times
and 10 times the signal-to-noise ratio and were calculated using a
mixed standard solution containing the available impurities at a
suitably low concentration level (ca. 0.1%). The calculated LOD
and LOQ values are summarized in Table II. For impurities which
were not available for purchase, the respective active substances
were used as a surrogate. This is a standard approach used in an-
alytical chemistry.
Response factors for known impurities
The response factors for the available impurities betamethasone,
betamethasone-21-valerate and 3-didehydrofusidic acid were cal-
culated by preparing solutions of equal concentration of each of
the impurities together with their respective APIs and compar-
ing the resulting peak areas. For the remaining known impurities
of FA, which were not available for purchase, the prescribed re-
sponse factors were taken directly from the EP monograph for
fusidic acid (7). In cases where no response factor was available,
the impurities were presumed to have the same response as the
API, i.e. factor 1.000. The approach taken is justified since the im-
purities cannot be purchased as pure substances and the purity
of the cream preparation is being measured at the same wave-
length as prescribed in the EP monograph for the API. The rele-
vant response factors are provided in Table III.
Analysis of development and stability samples
Thirty-eight trial batches of topical cream were analyzed with
the above-detailed purity procedure during formulation develop-
ment. It was observed that betamethasone-17-valerate was isom-
erizing rapidly to its corresponding 21-valerate isomer in some of
the formulations and that this process was both temperature and
pH dependent. Furthermore, the isomerization rate was also
shown to be significantly influenced by the concentration of
the primary emulsifier in the cream formulation. At higher con-
centrations of emulsifier, e.g. 5%, the isomerization occurs rapid-
ly with ca. 5% betamethasone-21-valerate being formed at pH
5.0+ 0.2 after 3 months storage under the conditions 258C/
60% relative humidity. Reducing the emulsifier concentration
to an appropriate level lead to a significant reduction of the isom-
erization rate, with only 0.1% betamethasone-21-valerate being
observed, under the same storage conditions and duration of
storage as above. Betamethasone-21-valerate and betamethasone
were the only degradants of BV observed in the cream samples,
the latter only being observed under suitable pH stress condi-
tions (pH . 7). In the final cream product only betametha-
sone-21-valerate is observed.
Figure 3. Chromatogram of a degraded cream sample analyzed after stressing under the conditions of 408C/75% RH at pH 7 for 2 months. The sample demonstrated a significant
degradation. HPLC conditions as provided in Table I. Peak 3 was not present in this particular sample. 1. Betamethasone. 2. 24,25-Dihydro-24,25-dihydroxyfusidic
acid. 3. 24,25-Dihydro-24,25-dihydroxyfusidic acid-21,25-lactone. 4. Betamethasone-17-valerate. 5. (24R)-24,25-dihydro-24,25-dihydroxyfusidic acid 21,24-lactone. 6. 26-Hydroxyfusidic
acid. 7. (24S)-24,25-dihydro-24,25-dihydroxyfusidic acid 21,24-lactone. 8. Betamethasone-21-valerate. 9. 26-Oxofusidic acid. 10. 3-Didehydrofusidic acid. 11. 11-Didehydrofusidic acid. 12.
16-Epideacetylfusidic acid. 13. Fusidic acid. 14. 16-Epideacetylfusidic acid-21,16-lactone. 15. Deacetylfusidic acid-21,16-lactone. 16. 11-Deoxyfusidic acid. U, unknown impurity.
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Fusidic acid proved stable in all of the development formula-
tions tested. Under accelerated (408C/75% RH) conditions the
final formulation showed an increase of the contents of the im-
purities 16-epideacetylfusidic acid, 16-epideacetylfusidic
acid-21,16-lactone as well as the impurities 3-didehydrofusidic
acid and 26-hydroxyfusidic acid. Of these impurities 16-epidea-
cetylfusidic acid and 16-epideacetylfusidic acid-21,16-lactone ap-
pear to be the major degradation products of fusidic acid as
demonstrated by Figures 2 and 3. The results of the accelerated
stability studies are presented in Table III. The product shows sig-
nificant degradation after 6 months storage. The mass-balance
values were considered acceptable (generally, 95–105% is ac-
ceptable). This further underlines the stability-indicating nature
of the procedure for the topical cream.
Conclusion
An RP-HPLC method was developed for the simultaneous quan-
titation of impurities of betamethasone-17-valerate and fusidic
acid in a topical cream preparation. The method was validated ac-
cording to current ICH guidelines and was demonstrated to be
selective, linear, precise, accurate, robust and sufficiently sensi-
tive within the validated range. The mass-balance values of de-
graded samples are acceptable, demonstrating the stability-
indicating power of the procedure for the topical cream. The
method is suitable for employment in the analysis of trial formu-
lations, release batches as well as during ICH stability testing.
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Table III
Accelerated Stability Data and Mass-Balance Values for the Topical Cream
408C/75% relative humidity Relative retention
time*
Response factor, ¢ 0 months 3 months 6 months Units
Assay of fusidic acid – – 100.0 99.5 99.2 The assay values are in % relative to the start value
*rrt values are relative to the fusidic acid peak
¢ Response factors should be divided
Purity of fusidic acid
24,25-Dihydro-24,25-dihydroxyfusidic acid 0.28 1.000 ,0.1 ,0.1 0.05
24,25-Dihydro-24,25-dihydroxyfusidic acid
21,25-lactone
0.41 1.000 ,0.1 ,0.1 ,0.1
(24R)-24,25-dihydro-24,25-dihydroxyfusidic acid
21,24-lactone
0.49 1.429 ,0.1 ,0.1 ,0.1
26-Hydroxyfusidic acid 0.50 1.000 0.07 0.17 0.31
(24S)-24,25-Dihydro-24,25-dihydroxyfusidic acid
21,24-lactone
0.56 1.429 0.05 0.08 0.13
Impurity N 0.57 1.000 ,0.1 ,0.1 ,0.1
26-Oxofusidic acid 0.63 3.333 ,0.1 ,0.1 0.06
3-Didehydrofusidic acid 0.85 1.074 0.16 0.20 0.23
11-Didehydrofusidic acid 0.87 1.000 ,0.1 ,0.1 ,0.1
16-Epideacetylfusidic acid 0.96 1.667 ,0.1 0.05 0.12
16-Epideacetylfusidic acid 21,16-lactone 1.12 1.000 ,0.1 ,0.1 0.17
Deacetylfusidic acid 1.14 1.000 ,0.1 ,0.1 ,0.1
Deacetylfusidic acid 21,16-lactone 1.15 1.667 ,0.1 0.05 ,0.1
9,11-Anhydrofusidic acid 1.20 1.000 ,0.1 ,0.1 ,0.1
11-Deoxyfusidic acid 1.24 1.000 ,0.1 ,0.1 ,0.1
Unknown impurities, single – – ,0.1 ,0.1 ,0.1
Total impurities – – 0.28 0.55 1.07
Mass-balance – – 100.3 100.1 100.3
Assay of Betamethasone-17-valerate – – 100.0 96.0 92.9
Purity of betamethasone-17-valerate
Betamethasone 0.12 1.154 0.12 0.13 0.09
Betamethasone-17-valerate 0.60 0.930 0.34 3.82 10.01
Unknown impurities, single – – ,0.1 ,0.1 ,0.1
Total impurities – – 0.46 3.95 10.10
Mass-balance – – 100.5 100.0 103.0
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